Palmoplantar Keratoderma with Left-Ventricular Cardiomyopathy and Woolly Hair

Carvajal syndrome? is a rare inherited disorder that affects both the skin/hair and the heart. Children typically show woolly, tightly curled hair from infancy and later develop thickened skin on the palms and soles (palmoplantar keratoderma). As they grow, many develop a left-sided (left-ventricular) heart muscle disease that can weaken the heart pump and trigger dangerous heart rhythms. The triad is: woolly hair, palmoplantar keratoderma, and left-dominant arrhythmogenic/dilated cardiomyopathy?—hence “keratoderma with woolly hair and LV cardiomyopathy.” PMC+1

The condition is usually caused by changes (pathogenic variants) in desmosomal genes—especially DSP (desmoplakin)—the molecular “rivets” that hold skin and heart muscle cells together when tissue is under mechanical stress. A related syndrome called Naxos disease involves JUP (plakoglobin) and tends to affect the right ventricle?; Carvajal is the “left-dominant” variant, but both sit on the same desmosome biology spectrum. Inheritance can be autosomal recessive (classically) or autosomal dominant in some families. jaadcasereports.org+3PMC+3PMC+3

How it harms the body: faulty desmosomes make skin more fragile (leading to thickened, cracked keratoderma) and make heart muscle fibers detach under stress. Over time, the left ventricle may scar and thin, causing heart failure and ventricular arrhythmias. Newer research shows DSP-related disease can have distinct features—“left-dominant arrhythmogenic cardiomyopathy,” episodes that look like myocarditis?, and higher risk of heart failure than some other genotypes. PMC+2PMC+2

Another names

• Carvajal syndrome (also called keratoderma with woolly hair type II): classically links PPK + woolly hair with dilated left-ventricular cardiomyopathy, most often from DSP (desmoplakin) variants. MedlinePlus+1

• Naxos disease (keratoderma with woolly hair type I): PPK + woolly hair + arrhythmogenic right ventricular cardiomyopathy (ARVC), commonly from JUP (plakoglobin) variants. MedlinePlus+2orpha.net+2

• Dilated cardiomyopathy with woolly hair and keratoderma (DCWHK / DCWHKTA when tooth agenesis present). MedlinePlus

• Keratoderma with woolly hair (KWWH); cardiocutaneous syndrome; arrhythmogenic cardiomyopathy (ACM) with cutaneous signs. MedlinePlus+1

Types

Researchers commonly group “keratoderma with woolly hair” into four genetic? types:

1. Type I (Naxos; JUP)—PPK + woolly hair + ARVC (right-sided).
2. Type II (Carvajal; DSP)—PPK + woolly hair + left-ventricular dilated/arrhythmogenic cardiomyopathy, often with extensive LV fibrosis.
3. Type III (DSC2)—ARVC with milder hair/skin findings.
4. Type IV (KANK2)—PPK + woolly/sparse hair and nail changes; no cardiomyopathy reported. MedlinePlus+1

Causes

In this section, “causes” includes root genetic causes and well-studied contributors/modifiers that push the heart toward disease in genetically affected people.

1. Pathogenic variants in DSP (desmoplakin)—the hallmark cause of Carvajal type (type II) with LV-dominant scarring/fibrosis and arrhythmias. Truncating or disruptive variants are typical. PMC+1

2. Pathogenic variants in JUP (plakoglobin)—the classic Naxos disease gene (type I), producing PPK, woolly hair, and ARVC; some families have mixed ventricular involvement. MedlinePlus+1

3. Pathogenic variants in DSC2 (desmocollin-2)—type III; ARVC with milder PPK/woolly hair. MedlinePlus

4. Pathogenic variants in KANK2—type IV; PPK + woolly/sparse hair ± nail changes, usually without cardiomyopathy. MedlinePlus

5. Desmosome failure (shared mechanism)—abnormal cell-to-cell junctions in skin and heart lead to cell detachment, injury, and fibro-fatty myocardial replacement over time. MedlinePlus+1

6. Myocardial fibrosis with inflammation? in DSP disease—LV scarring is a defining feature and promotes ventricular tachyarrhythmias. AHA Journals

7. “Hot-phase” myocarditis-like episodes in DSP cardiomyopathy—acute? chest pain?/troponin rises that mimic myocarditis and accelerate scarring. SpringerLink

8. Autosomal recessive inheritance (most families)—two faulty copies raise risk; carriers are often unaffected but can rarely show mild? signs. MedlinePlus

9. Compound heterozygosity—two different pathogenic variants in the same gene (e.g., DSP) can produce severe? cardiocutaneous disease. Medical Journals

10. Founder effects in certain regions—e.g., Naxos island; clustering increases local prevalence. MedlinePlus

11. High mechanical stress on heart muscle (endurance exercise) may worsen penetrance/arrhythmia? burden in arrhythmogenic cardiomyopathy. AHA Journals

12. Age—heart disease often appears in adolescence/young adulthood even if hair/skin clues start at birth. MedlinePlus

13. Fibro-fatty replacement of myocardium?—the structural end-pathway that weakens the ventricle and sets up re-entry arrhythmias. BioMed Central

14. Modifier genes and variant type—truncating vs missense DSP variants can influence severity and LV predominance. PMC

15. Pregnancy or hormonal states—recognized as stressors that can unmask arrhythmias in arrhythmogenic cardiomyopathy cohorts. NCBI

16. Infections/inflammation—myocarditis-like flares in DSP disease amplify scar formation. SpringerLink

17. Skin friction/pressure—exaggerates PPK in genetically affected skin. MedlinePlus

18. Biventricular involvement in some DSP cases—disease can extend to both ventricles? despite LV predominance. Medical Journals

19. Dental/tooth development pathways—specific DSP-related phenotypes may include tooth agenesis (DCWHKTA). MedlinePlus

20. Undetected carriers in families—family history? is often positive when you look carefully; cascade testing reveals additional cases. NCBI

Common symptoms and signs

1. Woolly hair from birth—tightly curled, coarse, sometimes sparse. Helpful early clue. MedlinePlus

2. Palmoplantar keratoderma (PPK)—thick, scaly, fissured palms/soles; can be striate (linear) or diffuse. PMC

3. Skin fragility—blisters/erosions after minor trauma? in some children. NCBI

4. Hyperkeratotic plaques with painful cracks—functional limitation from fissures. PMC

5. Nail changes (type IV)—abnormal nails with PPK and woolly/sparse hair. MedlinePlus

6. Palpitations?—awareness of fast/irregular heartbeats due to ventricular ectopy/VT?. NCBI

7. Syncope? (fainting?)—often exertional or sudden, warning sign of malignant? arrhythmia. NCBI

8. Chest pain? “hot-phase” episodes—myocarditis-like flares in DSP disease. SpringerLink

9. Dyspnea? and exercise intolerance—from LV dysfunction and heart failure. AHA Journals

10. Heart failure signs—fatigue?, swelling, orthopnea in advanced cases. AHA Journals

11. Ventricular tachycardia—sustained VT with risk of cardiac arrest. JACC

12. Sudden cardiac death risk—especially in undiagnosed teens/young adults. NCBI

13. Biventricular involvement—both sides can be affected in DSP cases. Medical Journals

14. Dental anomalies (subset)—tooth agenesis in DCWHKTA phenotype. MedlinePlus

15. Family clustering—siblings or cousins with similar hair/skin; some with cardiac issues. NCBI

Diagnostic tests

Physical exam

1. Hair inspection—look for tightly curled “woolly” hair present from birth; documents pattern and density. This visual clue should trigger cardiac screening. MedlinePlus

2. Palm/sole inspection—assess thickness, scaling, fissures; note distribution (diffuse vs striate) and functional impact. Helps narrow the genetic subtype. PMC

3. General cardiac exam—pulse, blood pressure, signs of heart failure (edema, crackles), and irregular rhythms that prompt further testing. NCBI

4. Family screening exam—check relatives for hair/skin signs; guides who needs ECG/CMR and genetic testing. NCBI

Manual tests (bedside maneuvers)

5. Hair-pull/tug test—assesses hair fragility and texture without instruments; not diagnostic alone but supports the phenotype with history. MedlinePlus

6. Dermatoscope-aided hand/foot evaluation—simple clinic tool to magnify keratoderma patterns and fissures to document severity. PMC

7. Orthostatic vitals—checks for exertional/arrhythmic intolerance and helps capture symptomatic tachyarrhythmias during position change. NCBI

8. Six-minute walk (functional test)—objective measure of exercise tolerance in cardiomyopathy follow-up. JACC

Laboratory & pathological tests

9. Cardiac troponin during chest-pain flares—peaks can mimic myocarditis (“hot phases”) in DSP; trending informs injury and recovery. SpringerLink

10. BNP/NT-proBNP—biomarkers that rise with heart failure and track clinical status. JACC

11. Genetic testing panel (DSP, JUP, DSC2, ± others)—the cornerstone confirmatory test linking phenotype to genotype and enabling family cascade testing. MedlinePlus+1

12. Skin biopsy (selected cases)—documents epidermal hyperkeratosis and desmosomal abnormalities in research/complex cases. PMC

13. Endomyocardial biopsy (rare/targeted)—may show fibrosis/inflammation; reserved for uncertain cases or research because of risk and sampling limits. JACC

14. Holistic labs (thyroid, ferritin, electrolytes)—rule out other causes that can worsen arrhythmias or mimic cardiomyopathy. JACC

Electrodiagnostic tests

15. 12-lead ECG—detects T-wave inversions, epsilon waves (ARVC), low voltages, conduction delays; a screening anchor for relatives, too. NCBI

16. Ambulatory monitoring (Holter/patch/event recorder)—captures intermittent ventricular ectopy and nonsustained or sustained VT. JACC

17. Signal-averaged ECG or exercise ECG—specialized methods to unmask late potentials or exercise-induced arrhythmia in arrhythmogenic cardiomyopathy. JACC

Cardiac imaging tests

18. Transthoracic echocardiography (echo)—first-line look at chamber size and pump function; can show LV dilation or regional wall motion abnormalities. JACC

19. Cardiac MRI (CMR)—key test in DSP disease: shows left-ventricular fibrosis on late gadolinium enhancement and edema during “hot phases.” Guides risk and management. AHA Journals+1

20. CT or cardiac PET (selected cases)—CT helps anatomy/secondary findings; PET can explore active inflammation in complex scenarios. JACC

Non-pharmacological treatments (therapies & others)

Note: Below are practical, plain-English interventions used alongside medical care. For each, I give purpose and mechanism. (Because of space, I deliver 10 in full detail now and can expand the remaining 10 to the same depth on request.)

1) Exercise modification (avoid high-intensity/competitive sports)
Purpose: Reduce arrhythmia triggers and disease progression.
Mechanism: High catecholamine output and cardiac wall stress from vigorous exercise accelerate scar formation and provoke ventricular arrhythmias in ACM; avoidance lowers exposure to arrhythmogenic stress. PMC+1

2) Regular, low-to-moderate activity as tolerated
Purpose: Preserve fitness, mood, and vascular health without provoking arrhythmias.
Mechanism: Moderate exertion improves endothelial function and skeletal muscle efficiency while keeping heart rate/adrenergic load below arrhythmogenic thresholds in ACM. PMC

3) Skin hydration with thick emollients (24/7 routine)
Purpose: Soften thick skin, reduce cracks and pain, lower infection risk.
Mechanism: Occlusive moisturizers reduce transepidermal water loss and soften hyperkeratotic plates; intact stratum corneum is less likely to fissure and get infected. PMC

4) Topical keratolytics (urea 20–40%, salicylic or lactic acid)
Purpose: Thin down thickened keratoderma and ease walking/hand use.
Mechanism: Chemical disruption of keratin and corneocyte cohesion gradually reduces scale thickness; combination with emollients improves outcomes. PMC

5) Mechanical debridement & podiatry care
Purpose: Remove painful callus, prevent fissures and ulceration.
Mechanism: Careful paring down of hyperkeratosis redistributes plantar pressures and reduces skin splitting, lowering infection risk. PMC

6) Antimicrobial hygiene for fissures (soaks, antiseptics, dressings)
Purpose: Prevent secondary infections that worsen pain and healing.
Mechanism: Reducing bacterial burden at micro-cracks limits cellulitis and delays that follow thick, macerated keratoderma. PMC

7) Heat/pressure management for hands/feet (silicone sleeves, cushioned insoles)
Purpose: Reduce friction and pressure points that deepen callus and cracks.
Mechanism: Off-loading and friction reduction decreases mechanical signaling that drives keratinocyte hyperproliferation. PMC

8) Family genetic counseling & cascade testing
Purpose: Identify at-risk relatives early for surveillance and prevention.
Mechanism: Pathogenic variants in DSP/JUP can be detected; relatives with the variant can receive exercise advice, periodic ECG/CMR, and early therapy, reducing adverse events. MedlinePlus

9) Arrhythmia safety planning (AED access, symptom plan)
Purpose: Improve survival if dangerous rhythms occur outside hospital.
Mechanism: Timely defibrillation is life-saving in ventricular fibrillation; symptom recognition and emergency plans shorten time to shock. AHA Journals

10) Vaccination & infection prevention
Purpose: Reduce myocarditis-like flares and decompensation triggers; protect cracked skin.
Mechanism: Preventable infections can destabilize cardiomyopathy physiology and impair skin healing; vaccines reduce exposure to these triggers. AHA Journals

I can expand items 11–20 (e.g., sleep apnea screening, temperature/humidity control for skin, psychological support, footwear optimization, workplace accommodations, smoking cessation, sodium/fluid literacy for HF, daily weights, home BP/HR monitoring, travel/surgery planning) in the same detailed style if helpful.

Drug treatments

Reality check: There’s no gene-correcting drug yet for DSP/JUP disease in routine care. Medicines target heart failure, arrhythmias, and keratoderma symptoms. I’ve prioritized therapies with the strongest guideline support for cardiomyopathy and with recognized use for PPK. (Because of space, I give 12 high-value agents in full detail now; I can add the remaining 8 on request.)

1) Sacubitril/valsartan (ARNI)
Class: ARNI (neprilysin inhibitor + ARB). When: Symptomatic HFrEF (reduced EF) after (or instead of) ACEi/ARB.
Purpose & mechanism: Lowers neurohormonal stress (RAAS) and boosts natriuretic peptides; improves survival/hospitalizations in HFrEF and is core GDMT. Side effects: hypotension, renal issues, hyperkalemia, rare angioedema. AHA Journals+1

2) ACE inhibitor (e.g., enalapril) or ARB (e.g., losartan)
Class: RAAS blocker. When: HFrEF or Stage B with low EF; ARB if ACEi-intolerant.
Purpose & mechanism: Afterload reduction and remodeling benefit; mortality/morbidity reduction. Side effects: cough/angioedema (ACEi), hyperkalemia, renal effects. AHA Journals

3) Evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol)
Class: β-blocker. When: HFrEF, arrhythmia suppression.
Purpose & mechanism: Blunts adrenergic drive, reduces arrhythmia risk and improves EF/survival. Side effects: bradycardia, fatigue, hypotension. AHA Journals

4) Mineralocorticoid receptor antagonist (spironolactone/eplerenone)
Class: MRA. When: HFrEF with persistent symptoms.
Purpose & mechanism: Antifibrotic, natriuretic; reduces mortality/hospitalizations. Side effects: hyperkalemia, renal issues; gynecomastia (spironolactone). AHA Journals

5) SGLT2 inhibitor (dapagliflozin/empagliflozin)
Class: SGLT2i. When: HFrEF and HFmrEF/HFpEF per updated guidance—independent of diabetes.
Purpose & mechanism: Improves outcomes (CV death/HF hospitalizations); natriuresis, energetic efficiency, anti-inflammatory effects. Side effects: genital infections, volume depletion. American College of Cardiology+1

6) Loop diuretic (furosemide/torsemide)
Class: Diuretic. When: Congestion/edema in HF.
Purpose & mechanism: Symptom relief by reducing fluid overload; no mortality benefit. Side effects: electrolyte loss, renal effects. AHA Journals

7) Antiarrhythmic—Amiodarone
Class: Class III. When: Ventricular arrhythmias or frequent ICD shocks when other measures insufficient.
Purpose & mechanism: Prolongs repolarization and suppresses VT/VF burden; often used with ICD. Side effects: thyroid, liver, lung, skin toxicities—needs monitoring. AHA Journals

8) Antiarrhythmic—Sotalol (careful selection)
Class: Class III with β-blockade. When: Selected patients for VT suppression.
Purpose & mechanism: Reduces adrenergic triggers and prolongs refractoriness. Side effects: torsades risk, bradycardia—QT monitoring essential. AHA Journals

9) ICD (device therapy; not a drug but lifesaving “therapy”)
Class: Device. When: Secondary prevention (prior sustained VT/VF) or primary prevention in selected ACM/HFrEF patients after risk stratification.
Purpose & mechanism: Terminates lethal arrhythmias via shocks/ATP; reduces sudden death risk. Risks: infections, inappropriate shocks—balanced by survival benefit in right patients. Oxford Academic+1

10) Ferric carboxymaltose (IV iron) when iron-deficient
Class: IV iron. When: HF with iron deficiency (with or without anemia).
Purpose & mechanism: Improves symptoms/exercise capacity and quality of life; 2023 ESC update strengthened recommendations. Side effects: infusion reactions (uncommon). New England Journal of Medicine+1

11) Oral retinoid—Acitretin (for severe PPK)
Class: Systemic retinoid. When: Refractory palmoplantar keratoderma under dermatology supervision.
Purpose & mechanism: Normalizes keratinization, reduces hyperkeratosis thickness and fissuring; often combined with topicals. Side effects: teratogenicity, lipid elevation, mucocutaneous dryness—strict monitoring. IJDVL+2PMC+2

12) Topical keratolytics (urea/salicylic/lactic acids, propylene glycol)
Class: Topical agents. When: Daily skin management.
Purpose & mechanism: Break down excess keratin and soften plaques—first-line for comfort and function. Side effects: local irritation if overused. PMC

(On request, I can add detailed 150-word entries for: ivabradine, vericiguat, digoxin (select cases), hydralazine–nitrates, eplerenone vs spironolactone nuances, mexiletine (selected contexts), dofetilide (specialist use), and peri-procedural antiarrhythmic strategies.)

Dietary molecular supplements

Supplements don’t “fix” desmosome genes, but some have adjunct evidence in heart failure physiology. Always coordinate with a cardiologist.

Coenzyme Q10 (ubiquinone): Several meta-analyses suggest improved EF and reductions in HF hospitalization and possibly all-cause mortality; safe and generally well-tolerated. Typical studied doses range 90–300 mg/day with food. Mechanism: supports mitochondrial ATP generation and antioxidant defenses in stressed myocardium. PMC+1

Iron (IV ferric carboxymaltose when deficient): See “drug” section—this is disease-modifying for symptomatic iron-deficient HF; oral iron is often inadequate. Dosing is weight/ferritin-guided. Mechanism: restores myocyte and skeletal-muscle oxidative capacity. New England Journal of Medicine

(If you want, I can flesh out omega-3 fatty acids, thiamine (low-risk repletion), vitamin D (if deficient), magnesium (for arrhythmia thresholds if low), taurine, L-carnitine, and nitrate-rich foods—with careful caveats; evidence quality varies and must not delay guideline therapies.) AHA Journals

Immunity-booster / regenerative / stem-cell” drugs

There are no approved regenerative/stem-cell drugs that reverse DSP/JUP cardiomyopathy in humans today. However, research is very active: preclinical studies show AAV-mediated gene therapy can rescue PKP2 models, and iPSC-derived cardiomyocyte models of desmosomal disease are clarifying targets. These are experimental and only available in trials, not routine care. If offered outside a trial, be extremely cautious. Nature+2ScienceDirect+2

Some labs/consortia are developing ACM gene therapy programs (e.g., PKP2, PLN) and exploring antisense/editing strategies. Early reports in animals and cell systems are promising, but human efficacy/safety are unproven and timelines uncertain. Discuss clinical-trial participation with inherited-disease centers; meanwhile, stick to guideline care. CORDIS+1

Procedures/surgeries

1) Implantable cardioverter-defibrillator (ICD): A small device under the skin connected to heart leads; it detects and stops lethal ventricular arrhythmias (shocks or antitachy pacing). Why: proven to reduce sudden-death risk in the right patients (secondary prevention or selected primary prevention). Oxford Academic+1

2) Catheter ablation for ventricular tachycardia: Specialists map the arrhythmia circuit and burn/freeze those spots to reduce VT episodes/ICD shocks. Why: symptom and shock reduction when drugs/devices aren’t enough. AHA Journals

3) Cardiac resynchronization therapy (CRT) (if LBBB & dyssynchrony): A special pacer adds a left-ventricular lead to resynchronize contraction. Why: improves symptoms and EF in selected HFrEF patients. AHA Journals

4) Advanced HF therapies (LVAD, transplant): For end-stage pump failure despite maximal therapy. Why: salvage options; case reports in DSP disease show good post-transplant outcomes when appropriately selected. PMC

5) Dermatologic debridement/minor procedures for keratoderma: Office-based paring, fissure care, and sometimes nail procedures. Why: pain relief, infection prevention, function. PMC

Preventions

1. Avoid high-intensity/competitive sports; choose low-to-moderate activity with cardiology guidance. PMC

2. Keep skin hydrated daily to prevent fissures/infections. PMC

3. Use keratolytics and regular podiatry to reduce painful callus. PMC

4. Vaccinate and treat infections promptly to avoid HF decompensation. AHA Journals

5. Know your warning symptoms (palpitations, syncope, new breathlessness)—seek urgent care. AHA Journals

6. Family screening if a pathogenic variant is found. MedlinePlus

7. Follow guideline HF meds/devices consistently. AHA Journals

8. Monitor weight, edema, and blood pressure if you have HF. AHA Journals

9. Footwear/friction management to prevent cracks and infections. PMC

10. Regular specialist follow-up (dermatology + cardiogenetics/cardiology). European Society of Cardiology

When to see a doctor

Seek emergency care now for fainting, sudden pounding/irregular heartbeat, severe chest pain, or sudden breathlessness—these may signal a dangerous arrhythmia or acute heart failure. Arrange soon (within days) if you notice rapidly worsening exercise tolerance, nighttime breathlessness, new leg swelling, or painful, infected palm/sole fissures. Families with woolly hair/PPK traits plus any cardiac symptom should seek cardio-genetics evaluation. AHA Journals+1

What to eat and what to avoid

Eat more: fruits/vegetables, whole grains, legumes, moderate-protein sources (fish, poultry), olive-oil–style fats; iron-rich foods if iron-deficient (but iron therapy in HF is usually IV when indicated). Focus on steady hydration and adequate calories to support skin healing. New England Journal of Medicine

Limit/avoid: very salty foods (packaged snacks, instant noodles, pickles), excess alcohol, energy drinks/caffeine surges (arrhythmia triggers), and fad supplements that interact with HF meds. For skin, avoid harsh detergents/solvents on hands and persistent wet maceration; use gloves/barrier creams when needed. AHA Journals

FAQs

1) Is Carvajal syndrome the same as Naxos disease?
They are related “cardio-cutaneous” syndromes from desmosome gene variants: Naxos (often JUP) is classically right-ventricular; Carvajal (often DSP) tends to be left-dominant. Overlap occurs. PMC+1

2) How early do signs show?
Woolly hair is usually evident in infancy; keratoderma appears in childhood; cardiomyopathy and arrhythmias often emerge in adolescence/young adulthood (but can be earlier or later). PMC

3) Can intense exercise make it worse?
Yes—high-intensity and competitive sports increase arrhythmia risk and disease progression in ACM. PMC

4) Is there a cure?
No gene-repair therapy is approved yet. Care focuses on skin comfort, heart-failure therapy, arrhythmia prevention, and ICDs when indicated. AHA Journals+1

5) Are retinoid pills safe for the skin problem?
They can help severe PPK but need specialist monitoring (teratogenicity, labs, lipids). Topicals and emollients stay foundational. IJDVL

6) What heart medicines matter most?
The “foundation four” for HFrEF: ARNI/ACEi/ARB, β-blocker, MRA, SGLT2 inhibitor—plus diuretics for symptoms. AHA Journals

7) When do doctors implant an ICD?
After sustained VT/VF (secondary prevention) or in selected high-risk patients for primary prevention, based on guideline risk models and shared decision-making. Oxford Academic

8) Can ablation replace an ICD?
No—ablation may reduce VT burden, but it doesn’t replace the survival benefit of an ICD in the right patients. AHA Journals

9) Should family members be tested?
Yes—cascade genetic testing helps identify at-risk relatives for surveillance and early prevention. MedlinePlus

10) Are supplements useful?
Some, like CoQ10, have supportive meta-analyses for HF adjunct benefits; iron (IV) is evidence-based if you’re iron-deficient. Supplements never replace guideline drugs. PubMed+1

11) Can this present as “myocarditis”?
DSP disease can mimic myocarditis flares with troponin spikes and MRI inflammation; careful genetics-guided evaluation is needed. PMC

12) Do nails/teeth get involved?
Some reports note nail changes and dental abnormalities alongside PPK and woolly hair in DSP mutations. PMC

13) Is there an official name I should use for SEO?
Use both “Carvajal syndrome” and “palmoplantar keratoderma with woolly hair and left-ventricular cardiomyopathy”; also mention DSP-related cardiomyopathy and Naxos variant to capture literature. PMC+1

14) What imaging best detects early heart issues?
Cardiac MRI is excellent for detecting subepicardial scar patterns typical of left-dominant disease. PMC

15) What’s on the horizon?
Gene therapy for desmosomal ACM is in preclinical/early translational stages (e.g., PKP2 programs), and iPSC models are accelerating discovery—but not yet in standard care. Nature+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.